First line afatinib vs gefitinib for patients with EGFR mutation positive NSCLC (LUX Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …

Martin Schuler,Eng-Huat Tan,Kenneth O’Byrne,Li Zhang,Michael Boyer,Tony Mok,Vera Hirsh,James Chih-Hsin Yang,Ki Hyeong Lee,Shun Lu,Yuankai Shi,Sang-We Kim,Janessa Laskin,Dong-Wan Kim,Catherine Dubos Arvis,Karl Kölbeck,Dan Massey,Angela Märten,Luis Paz-Ares,Keunchil Park
2019-01-01
Journal of Cancer Research and Clinical Oncology
Abstract:Purpose In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with treatment-naïve epidermal growth factor receptor mutation-positive non-small cell lung cancer. We report post hoc analyses of tolerability-guided dose adjustment for afatinib and summarize the clinical characteristics of patients who continued afatinib/gefitinib beyond initial radiological progression in LUX-Lung 7. Methods Patients received afatinib 40 mg/day or gefitinib 250 mg/day until investigator-assessed progression or beyond if beneficial. In case of selected treatment-related adverse events (TRAEs), the afatinib dose could be reduced by 10-mg decrements to minimum 20 mg (only dose interruptions were permitted with gefitinib). Results All …
What problem does this paper attempt to address?